The Cell Analysis and Specimen Banking Core is designed to support the clinical and basic science projects by centralizing common procedures (Aim 1) and centralizing tissue and specimen banking procedures (Aim 2). These include sample acquisition, processing, characterization, banking, and distribution;cell sorting;and analytical flow cytometry. The Myeloma Institute for Research and Therapy (MIRT) annually treats nearly 5,000 patients from across the US and the world. From this extensive patient base, Core B banks thousands of patient specimens, many of which are serially collected throughout the course of a patient's disease and treatment. Centralized sample acquisition and storage, together with enhanced database capabilities, is a tremendous resource for program project investigators, as well as a highly efficient operation. It will allow us to track samples and maintain records of expected data for each sample used, thus increasing the efficiency of data collection for all projects. These activities of the core will be enhanced by a constantly updated integrated database. A priority list for sample distribution will be established by the Core Oversight Committee, composed of the program PI and Project Leaders, and will be updated periodically to accommodate requirements of the different projects, such as cell numbers, sample type, and patient characteristics. This mechanism will greatly increase the efficiency of sample utilization by the different projects. A centralized sample processing service will avoid the need to establish the procedures in each investigator's laboratory, providing for uniform procedures and efficient use of materials. The flow cytometry and cell-sorting services offered will provide state-of-the-art support to the projects in this program application, which will be augmented by the expertise of core personnel.

Public Health Relevance

Core B is a service core and its impact relates to the relevance of the projects and the program it serves. By offering sample acquisition, processing, distribution, and specimen banking, Core B provides uniformity of procedures and patient specimen resources to all projects in this P01

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055819-19
Application #
8566720
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
19
Fiscal Year
2013
Total Cost
$458,587
Indirect Cost
$141,893
Name
University of Arkansas for Medical Sciences
Department
Type
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Alagpulinsa, David A; Ayyadevara, Srinivas; Yaccoby, Shmuel et al. (2016) A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Mol Cancer Ther 15:241-50
McDonald, James E; Kessler, Marcus M; Gardner, Michael W et al. (2016) Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res :
VÃ¥tsveen, Thea Kristin; Sponaas, Anne-Marit; Tian, Erming et al. (2016) Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro. J Hematol Oncol 9:75
Pawlyn, Charlotte; Kaiser, Martin F; Heuck, Christoph et al. (2016) The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clin Cancer Res 22:5783-5794
Weinhold, Niels; Ashby, Cody; Rasche, Leo et al. (2016) Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood 128:1735-44
Jethava, Yogesh; Mitchell, Alan; Epstein, Joshua et al. (2016) Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants. Clin Cancer Res :
Weinhold, N; Heuck, C J; Rosenthal, A et al. (2016) Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia 30:423-30
Pawlyn, C; Fowkes, L; Otero, S et al. (2016) Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia 30:1446-8
Heuck, C J; Jethava, Y; Khan, R et al. (2016) Inhibiting MEK in MAPK pathway-activated myeloma. Leukemia 30:976-80
Mitchell, Jonathan S; Li, Ni; Weinhold, Niels et al. (2016) Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun 7:12050

Showing the most recent 10 out of 272 publications